Peptide receptor radionuclide therapy
AssigneeThe Regents of the University of California
InventorJulie L. Sutcliffe
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype αvβ6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.
Claims22
A pharmaceutical composition comprising a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO.:
- 1).
A method for treating an αvβ6 integrin-related cancer, the method comprising administering a dose of a therapeutic conjugate of Formula I to a subject in need of treatment
- wherein 5G is a PEGylated peptide having an N-terminus, a C-terminus, and the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO.:
- 1);
- and wherein a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide.
A method for imaging a tumor, a cancerous lesion, or a cancer cell, the method comprising administering a diagnostic conjugate comprising Formula II and a pharmaceutically acceptable excipient to a subject
- wherein 5G is a PEGylated peptide having a, N-terminus, a C-terminus, and the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO.:
- 1);
- and wherein a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide.
Dependencies are inferred from the claim text.